 | Up a level |
Davies, A. J.; Zucca, E.; Ceriani, L.; Kryachok, I.; Ciccone, G.; Botto, B.; Balzarotti, M.; Tucci, A.; Rusconi, C.; Usai, S. V.; Pennese, E.; Arcaini, L.; Dabrowska‐Iwanicka, A.; Ferreri, A. J. M.; Merli, F.; Zhao, W.; Hodgson, D.; Rigacci, L.; Cellini, C.; Stelitano, C.; ... (2023). A RANDOMIZED TRIAL OF OBSERVATION VERSUS RADIOTHERAPY IN PRIMARY MEDIASTINAL B‐CELL LYMPHOMA PATIENTS WITH COMPLETE METABOLIC RESPONSE AFTER STANDARD IMMUNOCHEMOTHERAPY. Hematological oncology, 41(S2), pp. 48-50. Wiley 10.1002/hon.3163_19
Guckenberger, M.; Alongi, F.; Ricardi, U.; Scorsetti, M.; Balermpas, P.; Livi, L.; Lievens, Y.; Braam, P.; Jereczek- Fossa, B.A.; Stellamans, K.; Ratosa, I.; Peulen, H.; Widder, J.; Ramella, S.; Verbeke, L.; Dirix, P.; Khanfir, K.; Zilli, T.; Hemmatazad, H.; Jeene, P.; ... (2022). OC-0599 Factors associated with SBRT doses in oligometastatic disease: an EORTC/ESTRO OligoCare analysis. Radiotherapy and oncology, 170, S523-S524. Elsevier 10.1016/S0167-8140(22)02621-4
